On October 24, the Securities Times announced the winners of the 18th China Listed Company Value Evaluation. Eyebright Medical (688050) was recognized as one of the "Top 30 Value Companies on the Sci-Tech Innovation Board," and Chairman Dr. Xie Jiangbing was awarded the title of "Annual Sci-Tech Pioneer of China Listed Companies."

As an innovation-driven ophthalmic medical device manufacturer, EyebrightMedical's products span three key areas: surgical treatment, myopia management, as well as customer vision care, providing comprehensive solutions for cataract surgery, refractive correction, and vision health. In the surgical treatment sector, the company focuses on developing mid- to high-end medical devices for cataract surgery, with its core products being the self-developed "Proming" series of basic and functional intraocular lenses available at various price points.

In the field of myopia management, the company focuses on developing myopia control products and daily care items. Its core product is the "iBright" brand of orthokeratology lenses, complemented by defocus lenses and daily wear rigid contact lenses, providing patients with a variety of options for myopia management. In vision care, it specializes in myopia correction products, offering transparent and colored contact lenses under brands like "Leblet," "Ocula," and "TOPPOP," along with OEM services.

Eyebright Medical has been recognized as one of the top 30 companies on the Sci-Tech Innovation Board and awarded the title of Annual Sci-Tech Pioneer, demonstrating its strong growth potential. Its "Proming" aspheric intraocular lens has disrupted the international monopoly in the high-end market, addressing a domestic gap. With the launch of the continuous vision multifocal lens, Proming All-View, EyebrightMedical has solidified its position as a global leader in ophthalmic care, showcasing the strength of Chinese manufacturing.